Key result
In a 41-year-old male with warfarin-induced skin necrosis and protein C deficiency, dabigatran provided symptomatic relief and fewer side effects compared to initial treatment with rivaroxaban.
Why the study?
Does dabigatran improve tolerability compared to rivaroxaban in a patient with warfarin-induced skin necrosis and protein C deficiency?
Case Report (n=1)
Does dabigatran improve tolerability compared to rivaroxaban in a patient with warfarin-induced skin necrosis and protein C deficiency?
Dabigatran may be a tolerable alternative to rivaroxaban for anticoagulation in patients with warfarin-induced skin necrosis and protein C deficiency.
No takes yet. Share an insight, caveat, or question.
May support dabigatran consideration in protein C deficiency with warfarin necrosis; hypothesis-generating single-case observation.
Lai et al. (2017) conducted a case report in Warfarin-induced skin necrosis and protein C deficiency (n=1). Dabigatran vs. Rivaroxaban was evaluated on Symptomatic relief and side effects. In a 41-year-old male with warfarin-induced skin necrosis and protein C deficiency, dabigatran provided symptomatic relief and fewer side effects compared to initial treatment with rivaroxaban.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: